United States-based GeneCentric Therapeutics has acquired Select ImmunoGenomics LLC, a Chapel Hill, NC-based provider of advanced immunogenomic, data analysis and biomarker development services to support the development of immuno-oncology drugs, it was reported on Friday.
As a result of the transaction, it is claimed that the integrated company will have a comprehensive, integrated set of RNA-based solutions to improve drug development by identifying the right patients for oncology drugs, improving response rates and durability, and ultimately patient outcomes.
Financial terms of the deal were not revealed.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886